长沙晚报全媒体记者 贾凯清 通讯员 彭雁 健康产业一头连着民生福祉，一头连着经济发展。在长沙这片创新热土上，生物医药上市企业以19家的 数量、超2000亿元的总市值，成为驱动区域经济与产业创新的核心力量。 向城西望去，以湘江集团新城医疗公司打造的湘江数字健康产业园为核心载体，一个百亿级的生物医药 产业集群在这里加速成长，成为长沙建设全球研发中心城市征程中一张闪亮的"产业名片"。 平台赋能：助力企业创新提速 生物医药企业为产品办证需要跑多远？在湘江数字健康产业园，答案是就在"家门口"。 今年5月，湖南湘江新区药品审评核查中心正式落户园区。该中心将依托省药监局在政策指导、技术支 撑和审评服务等方面的专业性，进一步优化审评流程，打通创新药械上市的"最后一公里"。 据了解，审评核查中心还将推行"服务专员+绿色通道"机制，实现创新药械审批周期提速。正式投入使 用后，业务时限将较目前湖南省法定时限缩短40%左右。 除了为企业搭建"审评高速路"，为保证企业的算力需求，园区内还特别设置了一个"智慧大脑"——互联 网数据中心IDC机房。据介绍，该机房规划建设1000个机柜，可提供IDC基础服务、云计算服务、数据 综合应用服务及 ...

Core Insights - The report by CCID Consulting highlights that Urumqi High-tech Zone (New District) ranks 71st in the national park economy top 100 list for 2025, improving by 2 positions from 2024 [1] - In the high-quality development of park industries, particularly in biomedicine, it ranks 62nd, advancing 36 positions from the previous year, making it the only park in Xinjiang to be included in the national top 100 [1] Group 1: Industry Development - Urumqi High-tech Zone has significantly developed its biomedicine and health industry, forming a comprehensive industrial cluster that includes planting, research and development, production, sales, and distribution [1] - The biomedicine industry in the high-tech zone accounts for over 70% of Xinjiang's biomedicine enterprises, with an overall scale nearing 24 billion yuan in 2024 [1] - Key projects such as Xinjiang Huashidan Pharmaceutical International Industrial Park and Yinduo Pharmaceutical National Medicine Industrial Park are accelerating the industry's advancement towards high-end, intelligent, and green development [1] Group 2: Company Initiatives - Xinjiang Yinduo Pharmaceutical Co., Ltd. has introduced an advanced automated packaging production line, achieving a threefold increase in production efficiency, with plans for large-scale production by April next year [2] - The company has over 50 years of pharmaceutical heritage and has developed a complete industrial chain for ethnic medicine, with 82 products approved by the National Medical Products Administration, including 12 ethnic medicine products [2] - The new project by Xinqikang Pharmaceutical, with a total investment of 210 million yuan, is set to enhance production capacity significantly, while Xinjiang Huashidan Pharmaceutical International Industrial Park is also under construction to quadruple its production capacity [2] Group 3: Future Plans - Urumqi High-tech Zone aims to strengthen its role as a core carrier for innovation resources and industrial upgrades by focusing on the biomedicine industry cluster [3] - The zone has recommended 77 technology plan projects for 2025, with a total investment of nearly 600 million yuan [3] - Future initiatives include enhancing the entire biomedicine industry chain from research and development to sales and distribution, attracting more enterprises and supporting projects [3]

Core Insights - The establishment of the Overseas Returnee Town (Guangzhou Biomedicine) in the Guangzhou Development Zone and Huangpu District has become a hub for returning talents and innovative enterprises in the biomedicine sector, showcasing a successful model for attracting overseas professionals [1][8][10] Group 1: Development of the Biomedicine Industry - The Guangzhou Development Zone and Huangpu District have built a complete biomedicine industry chain, integrating research, transformation, and production across different areas [1][4] - The core area of the Overseas Returnee Town has attracted around 30 well-known innovative enterprises, creating a positive cycle of talent and industry [3][4] - The "1+N" multi-core model of the town promotes regional collaboration and serves as a crucial hub for innovation [7][10] Group 2: Infrastructure and Support Systems - The dual centers, Phoenix Valley Overseas Returnee Center and International Biomedicine Innovation Center, provide comprehensive support services for the ecosystem [3][4] - The Guangzhou Guigu Technology Park serves as a demonstration area for the Overseas Returnee Town, focusing on innovation and entrepreneurship [4][6] - The establishment of a 20 billion yuan operational management guiding fund aims to attract social capital and enhance the development of the biomedicine sector [10][14] Group 3: Talent Attraction and Retention - The region has successfully attracted returning talents by offering favorable entrepreneurial policies and a conducive environment for innovation [8][10] - The integration of overseas talents into the local innovation network is facilitated by a ten-service operational system [6][12] - The returnee town is designed to support the rapid transformation of scientific achievements into marketable products [4][12] Group 4: Financial Support and Investment - A 50 billion yuan science and technology mother fund has been established to invest in strategic emerging industries, including those involving returning talents [13][14] - Approximately 76.11 billion yuan has been invested in 274 enterprises, with 18.54 billion yuan specifically allocated to returning entrepreneurial companies [14] - The innovative financial model allows for a 100% loss on single projects, effectively reducing early-stage investment risks [13][14]

Core Viewpoint - Shanghai is actively developing its biopharmaceutical industry, aiming to create a world-class industrial cluster with significant investment and growth potential [4][8]. Investment Initiatives - Shanghai Guotou Company has established a biopharmaceutical industry mother fund with a total scale of 22.5 billion yuan, focusing on early-stage investments and long-term support for hard technology [6]. - The Shanghai Future Industry Fund, with a total scale of 15 billion yuan, aims to leverage fiscal funds to promote original innovation and technology transformation [6]. - By October 2025, these funds have collectively decided on investments of nearly 6 billion yuan in biopharmaceutical sub-funds, with a market selection of 18 sub-funds [6]. Industry Growth - The biopharmaceutical industry in Shanghai has shown continuous growth, increasing from 761.71 billion yuan in 2021 to an estimated 1 trillion yuan in 2025, with a compound annual growth rate of 8.94% [9]. - In the first half of 2025, the industry reached 500.56 billion yuan, indicating strong momentum towards surpassing the 1 trillion yuan mark [9]. Company Landscape - As of the end of 2024, there are 2,183 regulated biopharmaceutical enterprises in Shanghai, with leading companies like United Imaging Healthcare and Innovent Biologics maintaining significant market positions [10]. - Notably, 19 of the top 20 global pharmaceutical and medical device companies have established headquarters or R&D centers in Shanghai, highlighting the city's attractiveness for high-caliber projects [10]. Collaborative Efforts - A recent signing ceremony involved 10 institutions, including major investment firms, indicating a robust collaborative environment within the biopharmaceutical sector [4][6]. - The establishment of industrial clusters in areas like Pudong and Minhang is aimed at enhancing resource concentration and fostering innovation [10].

Core Insights - Shanghai's biopharmaceutical industry is experiencing rapid growth, with 38 license-out transactions expected to reach $30.7 billion in 2024, accounting for nearly one-third of the national total [1] - The industry has a compound annual growth rate of 8.94%, with a projected market size exceeding 1 trillion yuan this year [1] - Shanghai is building a world-class innovation ecosystem to enhance its role as a leading biopharmaceutical hub [1] Industry Development - Since 1993, biopharmaceuticals have been a key focus in Shanghai, with industrial output surpassing 200 billion yuan by 2024 [2] - Recent regulations and action plans have been implemented to support innovation across the entire biopharmaceutical value chain [2] - The establishment of the Shanghai Clinical Innovation Transformation Research Institute aims to facilitate the commercialization of clinical results from hospitals [2][3] Clinical Innovation - The clinical results commercialization model allows hospitals to transfer patent rights to the institute, which then partners with investors to form companies [3] - This model addresses challenges hospitals face in managing clinical results and enhances the efficiency of technology transfer [3] Foreign Investment and Local Innovation - Shanghai has attracted major international pharmaceutical companies, with 19 out of the top 20 global firms establishing headquarters or R&D centers in the city [5] - The city is fostering collaboration between multinational and local companies, enhancing innovation capabilities [5][6] Policy Support - Shanghai has introduced comprehensive policies covering the entire biopharmaceutical industry chain, promoting R&D and manufacturing [8] - The city has recognized significant achievements in biopharmaceutical innovation, such as the development of the first domestically produced targeted drug for colorectal cancer [8][9] Financial Investment - The biopharmaceutical sector relies heavily on patient capital due to its high-risk and long-cycle nature [12] - Shanghai has established a 22.5 billion yuan biopharmaceutical industry fund to support strategic mergers and acquisitions [13][14] - From 2021 to 2024, the sector has seen cumulative financing of 238.37 billion yuan, with 1,494 financing events [13]

Core Insights - The competitiveness of the biopharmaceutical industry ultimately reflects the cluster effect [1][11] - The biopharmaceutical industry is a core track of global technological revolution and industrial transformation, serving as a key indicator of regional economic high-quality development [2] Industry Development - The Yangtze River Delta region, centered around Shanghai Zhangjiang and Suzhou BioBAY, has established a first-mover advantage in the biopharmaceutical field due to early policy layouts, dense research resources, and a complete industrial chain [2] - Guangzhou Huangpu District has not lagged despite being a latecomer; it has optimized its policy system, built talent aggregation platforms, and focused on breakthroughs in niche markets, gradually compensating for industrial chain shortcomings [2][12] Key Companies and Innovations - Yunzhou Biotech, founded by Dr. Lan Tian in Huangpu District in 2014, focuses on gene delivery, a critical link between basic research and clinical application [3] - The company developed the world's first intelligent design and ordering platform for gene carriers, integrating over 120 carrier systems and more than 2 million carrier components, significantly lowering the barriers for researchers [4][5] - Yunzhou Biotech has become the world's largest custom gene carrier supplier, serving over 7,000 institutions in more than 130 countries, with a cumulative delivery of over 1 million carriers by September 2024 [5][6] Market Position and Achievements - In 2023, Yunzhou Biotech achieved a valuation of 7 billion, becoming a unicorn and the first biopharmaceutical company in Guangzhou to reach this status [6] - The company has established a full-service capability in the gene drug development chain, including CRO and CDMO services, with its products approved for clinical trials in the U.S. [6][7] Competitive Landscape - Innovation in drug development is a core competitive advantage in the biopharmaceutical industry, with companies like Kangfang Biopharma emerging as leaders in the field [8] - Kangfang Biopharma has developed over 50 innovative drug candidates, with 24 products undergoing clinical trials, and has successfully commercialized 7 first-class new drugs [10] Ecosystem and Collaboration - Huangpu District's "bending overtaking" is not merely the success of a single enterprise but a result of creating a quality industrial ecosystem that fosters collaboration between leading external companies and local enterprises [12] - The presence of major companies like Hengrui Medicine and Nuocheng Jianhua in Huangpu has attracted a network of supporting enterprises, enhancing the regional industrial chain [13][14]

Core Insights - The Boao Lecheng International Medical Tourism Pilot Zone held a conference on August 30, where 13 leading domestic biopharmaceutical companies signed agreements, with a total investment expected to exceed 3 billion yuan [1][2] - The collaboration aims to leverage the technological advantages of these companies along with the policy benefits of Hainan Free Trade Port to promote the application of new technologies, products, and solutions in the pilot zone [1] - The initiative seeks to establish a comprehensive biopharmaceutical industry cluster that integrates innovation research and development, pilot transformation, large-scale production, and clinical application [1] Group 1 - The Lecheng Pilot Zone is recognized as the only "medical special zone" in China and plays a crucial role in the construction of Hainan Free Trade Port [2] - The zone has developed a full-chain service system covering the rapid introduction of international innovative drugs and medical devices, clinical application, registration approval, and manufacturing [2] - It has been at the forefront of clinical transformation applications for new biomedical technologies such as cell therapy and gene editing, having approved 11 cutting-edge medical technology projects [2] Group 2 - The conference included presentations on the practical exploration and development opportunities of biomedical new technologies in the Lecheng Pilot Zone [1] - There was also an interpretation of Hainan Province's policies to further support the high-quality development of the biopharmaceutical industry [1] - The event highlighted the promotion of regional headquarters, research and development centers, and production bases to enhance the industry’s capabilities [1]

Core Viewpoint - The Jiangsu Free Trade Zone aims to enhance the biopharmaceutical industry through an open innovation development plan, targeting significant growth and modernization by 2030 [4][5]. Group 1: Overall Requirements - The plan is guided by Xi Jinping's thoughts and aims to create a globally influential biopharmaceutical hub in Jiangsu, focusing on high-quality development and safety [4][5]. Group 2: Enhancing R&D Innovation Capabilities - The initiative supports major national science and technology projects in biopharmaceuticals, emphasizing breakthroughs in innovative drugs and high-end medical devices [5][6]. - It promotes the application of big data and artificial intelligence in drug design and medical device manufacturing [5][6]. - The establishment of a national biopharmaceutical technology innovation center in Suzhou is encouraged to facilitate technology transfer and application [6][7]. Group 3: Improving Product Approval Services - The plan aims to optimize drug review services and enhance the approval process for innovative drugs and medical devices [8][9]. - It includes strengthening inspection and testing capabilities for biological products, particularly vaccines [8][9]. Group 4: Building a Biopharmaceutical Production and Distribution System - The initiative focuses on developing advanced manufacturing clusters for biopharmaceuticals and high-end medical devices [9][10]. - It aims to enhance customs facilitation for medical devices entering special regulatory zones [9][10]. Group 5: Enhancing Procurement and Usage Policies - The plan encourages the inclusion of eligible innovative drugs in the national medical insurance catalog and aims to streamline the approval process [10][11]. - It explores the introduction of AI-assisted diagnostic technologies in medical services [10][11]. Group 6: Increasing Support for Key Elements - The initiative proposes a market-oriented evaluation mechanism for talent in the biopharmaceutical sector [11][12]. - It supports financial backing for innovative biopharmaceutical companies through various funding avenues [11][12]. Group 7: Ensuring Safety and Risk Management - The plan emphasizes the importance of safety management in biopharmaceutical production and the need for robust risk assessment mechanisms [13][14]. - It aims to align regulatory capabilities with international standards to enhance drug and medical device oversight [13][14].

Core Viewpoint - The development of Hainan University School of Pharmacy has significantly improved, with its academic ranking rising from 119th to 49th nationally, contributing to the cultivation of local pharmaceutical talents for the Hainan Free Trade Port [1] Group 1: Institutional Development - The School of Pharmacy has established a complete training system for undergraduate, master's, and doctoral programs, and has been recognized as a national-level first-class undergraduate program [1] - The institution has successfully attracted and trained 50 high-level talents to enhance its educational and research capabilities [1] Group 2: Industry Collaboration - The School of Pharmacy relocated to Haikou National High-tech Zone to better align with enterprise needs, collaborating with leading pharmaceutical companies to establish a provincial-level biopharmaceutical engineering industry college [1] - Agreements have been signed with various enterprises in the park for practical teaching and internship bases, aiming to create a collaborative entity that integrates industry, education, and research [1] Group 3: Research and Development Initiatives - The institution is addressing the innovation capability issues faced by local biopharmaceutical companies by creating a comprehensive drug research and evaluation platform [2] - A proposal has been submitted to establish a raw material drug park in the Yangpu Economic Development Zone to enhance the local pharmaceutical industry's supply chain and support its transformation and upgrading [2] Group 4: Government Support and Project Implementation - The proposal to develop a raw material drug park has received significant attention from relevant departments and local governments, with several projects already initiated in Yangpu [3] - The ongoing development of the Hainan Free Trade Port is expected to attract more companies to engage in raw material drug production and research, addressing critical challenges in the biopharmaceutical industry [3]

Core Viewpoint - The opening of the new R&D transformation production base by Xin Kai Yuan in Songjiang marks a significant milestone for the company and contributes to the development of the biopharmaceutical industry in the region [2][3][4] Group 1: Company Overview - Xin Kai Yuan is the first domestic high-tech enterprise focused on the production, R&D, and sales of PVP series products and PVME/MA series products, with over 1,000 clients globally [2] - The company has been planning its medical business headquarters in Shanghai Songjiang since 2018, aiming to strengthen its existing precision medicine and women's health businesses [2] - Xin Kai Yuan collaborates deeply with its invested companies, Huada Bio and Yongtai Bio, to establish a fully autonomous CAR-T cell production base with complete intellectual property rights [2] Group 2: Industry Impact - The establishment of the "Yuan Yin Nuo Fang" biopharmaceutical incubator and the signing of a commercial production base agreement for CAR-T cell drugs with Huada Bio will enhance production efficiency and reduce costs [3] - The new base aligns with the strategic goals of the Songjiang District, which aims to create a world-class biopharmaceutical industry cluster, thereby boosting R&D capabilities in cutting-edge fields like cell therapy and gene technology [3] - The operation of the new base is expected to drive innovation and international development in precision medicine and high-end fine chemicals in China [3][4]